Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network

Cure51's CEO Nicolas Wolikow: "Reverse-Engineering the Cure to Cancer: A New Paradigm in Oncology Research"

WE’RE THRILLED TO WELCOME ASHLEY LAKNER, PHD, AS OUR NEW CHIEF SCIENTIFIC OFFICER (CSO)!

Cure51's CEO Nicolas Wolikow and Yann Bizien addressing rising rates of early-onset Cancer in France

What is a Clinical Trial in Cancer Care? A Complete Guide for Patients

Discover how Elio, Cure51’s multi-agent AI system, connects clinical, multi-omics and research data to accelerate Cancer discovery and innovation.

CURE51 achieves ISO 27001 & HDS certifications for secure health data hosting GDPR-compliant platform for pharmaceutical & oncology research

Happy New Year 2026! Reflecting on Cure51’s Cancer Research Progress & the Rosalind Study

Rosalind Study Launches in Dubai in collaboration with Mediclinic Middle East City Hospital and Dr. Shaheenah Dawood to Advance Cancer Research

Despite pessimistic diagnoses, some patients live for many years, or are even cured. Cure51 studies these extraordinary cases to eradicate Cancer.

How are TechBio companies redefining the future of drug discovery and development?

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Explicyte has been selected by biotech company Cure51 to participate in the world's largest study.

Patient who overcame brain tumour to play key role in Cure51 ‘super-survivor’ cancer study.

French techbio company Cure51 has partnered with NVIDIA to accelerate research into a rare phenomenon: cancer patients who survive against the odds.